Published in Heart Vessels on November 27, 2006
Treatment strategy and clinical outcome in Japanese patients with atrial fibrillation. Heart Vessels (2009) 1.03
Usefulness of rate regulation through continuous ventricular pacing in patients with drug-controlled slower atrial fibrillation and normal or depressed left ventricular systolic function. Heart Vessels (2008) 0.83
A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med (2002) 16.31
Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med (1982) 8.62
A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med (2002) 8.37
Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med (1995) 7.83
Echocardiographic predictors of nonrheumatic atrial fibrillation. The Framingham Heart Study. Circulation (1994) 4.52
Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol (1994) 4.08
Rhythm or rate control in atrial fibrillation--Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet (2000) 3.36
Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol (2003) 2.73
Atrial fibrillation in elderly patients: prevalence and comorbidity in general practice. BMJ (1996) 2.57
Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation (1990) 2.51
Cardioversion guided by transesophageal echocardiography: the ACUTE Pilot Study. A randomized, controlled trial. Assessment of Cardioversion Using Transesophageal Echocardiography. Ann Intern Med (1997) 2.38
Antithrombotic therapy in atrial fibrillation. Chest (1995) 2.08
Relation between echocardiographically determined left atrial size and atrial fibrillation. Circulation (1976) 2.08
Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation and flutter. Am J Cardiol (1991) 2.02
Functional status in rate- versus rhythm-control strategies for atrial fibrillation: results of the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Functional Status Substudy. J Am Coll Cardiol (2005) 1.77
Factors determining maintenance of sinus rhythm after chronic atrial fibrillation with left atrial dilatation. Am J Cardiol (1989) 1.50
Echocardiographic and clinical predictors for outcome of elective cardioversion of atrial fibrillation. Am J Cardiol (1989) 1.40
Factors affecting cardioversion of atrial arrhythmias with special reference to quinidine. Br Heart J (1968) 1.34
Recurrence of paroxysmal atrial fibrillation or flutter after successful cardioversion in patients with normal left ventricular function. Am J Cardiol (1993) 1.11
Factors influencing persistence of sinus rhythm after DC shock treatment of atrial fibrillation. Acta Med Scand (1971) 1.08
Doppler echocardiographic predictors of recurrence of atrial fibrillation after cardioversion. Am J Cardiol (1988) 0.94
Amiodarone for refractory atrial fibrillation. Am J Cardiol (1986) 0.91
Amiodarone for maintenance of sinus rhythm after conversion of atrial fibrillation in the setting of a dilated left atrium. Am J Cardiol (1987) 0.86
Restoration and maintenance of sinus rhythm after mitral valve surgery for mitral stenosis. Am J Cardiol (1984) 0.84
Amiodarone versus quinidine in the prophylaxis of atrial fibrillation. Acta Cardiol (1981) 0.82
Factors influencing long term persistence of sinus rhythm after a first electrical cardioversion for atrial fibrillation. Pacing Clin Electrophysiol (1998) 0.80
Serial antiarrhythmic therapy: role of amiodarone in prevention of atrial fibrillation recurrence--a lesson from the HOT CAFE Polish Study. Cardiology (2005) 0.79
2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73
2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J (2013) 9.54
Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med (2014) 9.33
Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med (2005) 9.27
Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59
2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J (2014) 6.32
Clinical Features and Outcomes of Takotsubo (Stress) Cardiomyopathy. N Engl J Med (2015) 6.00
Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol (2009) 5.31
Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med (2013) 4.98
Heat effects on mortality in 15 European cities. Epidemiology (2008) 4.63
Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol (2004) 3.63
Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J (2004) 3.51
The temporal pattern of mortality responses to air pollution: a multicity assessment of mortality displacement. Epidemiology (2002) 3.21
Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation (2013) 2.82
Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries. Eur Heart J (2009) 2.68
[Apical ballooning syndrome in a 57-year-old woman during premedication for general anaesthesia]. Kardiol Pol (2006) 2.67
Resistance to oral antiplatelet drugs--a Position Paper of the Working Group on antiplatelet drug resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society. Kardiol Pol (2008) 2.63
Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest (2006) 2.43
Cardiac troponin T monitoring identifies high-risk group of normotensive patients with acute pulmonary embolism. Chest (2003) 2.40
Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension. Hum Mutat (2006) 2.30
The temporal pattern of respiratory and heart disease mortality in response to air pollution. Environ Health Perspect (2003) 2.22
Regional differences in determining cardiovascular diseases as the cause of death in Poland: time for change. Kardiol Pol (2012) 2.06
OSACS score-a new simple tool for identifying high risk for Obstructive Sleep Apnea Syndrome based on clinical parameters. Anatol J Cardiol (2014) 1.99
Clinical, biochemical and genetical resistance to clopidogrel in a patient with the recurrent coronary stent thrombosis--a case report and review of the literature. Int J Cardiol (2005) 1.95
Management of grown up congenital heart disease. Eur Heart J (2003) 1.94
Efficacy of multi-electrode duty-cycled radiofrequency ablation in patients with paroxysmal and persistent atrial fibrillation. Cardiol J (2013) 1.93
Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation (2011) 1.92
The role of cardiac registries in evidence-based medicine. Eur Heart J (2010) 1.83
Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. J Am Coll Cardiol (2009) 1.78
Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol (2002) 1.77
Outcome after cardiopulmonary resuscitation in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med (2002) 1.72
Mean platelet volume on admission predicts impaired reperfusion and long-term mortality in acute myocardial infarction treated with primary percutaneous coronary intervention. J Am Coll Cardiol (2005) 1.71
Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol (2008) 1.69
Atrial septostomy in treatment of end-stage right heart failure in patients with pulmonary hypertension. Chest (2007) 1.66
Pertussis in Poland. Int J Epidemiol (2004) 1.64
Pregnancy outcomes in pulmonary arterial hypertension in the modern management era. Eur Respir J (2012) 1.63
Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol (2003) 1.62
2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. Rev Esp Cardiol (Engl Ed) (2016) 1.61
Management of familial heterozygous hypercholesterolemia: Position Paper of the Polish Lipid Expert Forum. J Clin Lipidol (2013) 1.58
Suppression of paroxysmal atrial tachyarrhythmias--results of the SOPAT trial. Eur Heart J (2004) 1.58
Influence of C3435T multidrug resistance gene-1 (MDR-1) polymorphism on platelet reactivity and prognosis in patients with acute coronary syndromes. Kardiol Pol (2009) 1.54
Leptin in acute myocardial infarction and period of convalescence in patients with type 2 diabetes mellitus. Kardiol Pol (2010) 1.47
Cognitive disorders in elderly patients with permanent atrial fibrillation. Kardiol Pol (2009) 1.46
Availability of automated external defibrillators in the city of Warsaw - status for May 2009. Kardiol Pol (2010) 1.45
Plasma adiponectin levels in acute myocardial infarction and during the postinfarction recovery period in patients with type 2 diabetes mellitus. Kardiol Pol (2011) 1.44
Efficacy of catheter ablation in patients with an electrical storm. Kardiol Pol (2011) 1.43
Comparison of on-admission ST-segment elevation tako-tsubo patients and myocardial infarction women: in-hospital course and long-term follow-up. Kardiol Pol (2012) 1.43
The effects of left ventricular diastolic function on natriuretic peptide levels after cardioversion of atrial fibrillation. Kardiol Pol (2009) 1.42
What has changed in the treatment of ST-segment elevation myocardial infarction in Poland in 2003-2009? Data from the Polish Registry of Acute Coronary Syndromes (PL-ACS). Kardiol Pol (2011) 1.42
CHA2DS2-VASc and R2CHA2DS2-VASc scores have predictive value in patients with acute coronary syndromes. Pol Arch Med Wewn (2015) 1.41
Access to selected diagnostic procedures in the management of heart failure patients in Poland - POLKARD 2005. Kardiol Pol (2010) 1.41
IgG, IgM and inflammatory markers serum concentration in patients with acute coronary syndrome: a pilot study. Kardiol Pol (2012) 1.41
Efficacy and tolerability of oral propafenone versus quinidine in the treatment of recent onset atrial fibrillation: A randomized, prospective study. Cardiol J (2009) 1.41
Influence of different antiplatelet treatment regimens for primary percutaneous coronary intervention on all-cause mortality. Eur Heart J (2009) 1.41
No correlation between atrial natriuretic peptide concentrations and echocardiographic measurements of left atrial size or left ventricular size and function in patients with persistent atrial fibrillation. Pacing Clin Electrophysiol (2005) 1.41
Abrasions of the outer silicone insulation of endocardial leads in their intracardiac part: a new mechanism of lead-dependent endocarditis. Europace (2012) 1.40
Atrial natriuretic peptide level after cardioversion of chronic atrial fibrillation. Int J Cardiol (2002) 1.40
Can thromboembolic risk be associated with erectile dysfunction in atrial fibrillation patients? Cardiol J (2015) 1.39
Transcatheter aortic valve implantation using direct aortic access: first procedures in Poland. Kardiol Pol (2012) 1.39
'Syringe-in-the-pocket'--a new approach to the outpatient thromboembolic prophylaxis of recurrent atrial fibrillation. Cardiology (2007) 1.39
Age-related gap in the management of heart failure patients. The National Project of Prevention and Treatment of Cardiovascular Diseases--POLKARD. Cardiol J (2012) 1.39
Osborn waves during therapeutic hypothermia in a young ST-ACS patient after out-of-hospital cardiac arrest. Kardiol Pol (2013) 1.39
Effects of exercise testing on natriuretic peptide secretion in patients with atrial fibrillation. Kardiol Pol (2009) 1.39
Evaluation of safety and the success rate of cryoballoon ablation of the pulmonary vein ostia in patients with atrial fibrillation--a preliminary report. Kardiol Pol (2010) 1.39
Rate vs rhythm control in patients with atrial fibrillation: a meta-analysis. Arch Intern Med (2005) 1.24
End points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives. J Am Coll Cardiol (2004) 1.24
Previously known and newly diagnosed atrial fibrillation: a major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction. Eur J Heart Fail (2006) 1.22
Gender-specific mortality associated with alcohol consumption in Poland in transition. Addiction (2005) 1.19
Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel. Circ J (2008) 1.16
Aortic dissection involving ostium of right coronary artery as the reason of myocardial infarction. Eur Heart J (2005) 1.15
Biomarker-based risk assessment model in acute pulmonary embolism. Eur Heart J (2005) 1.12
Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J (2012) 1.11
[PM/ICD lead extraction - most difficult and potentially hazardous electrotherapy procedure - logistic and training problems]. Kardiol Pol (2010) 1.10
Disturbed right ventricular ejection pattern as a new Doppler echocardiographic sign of acute pulmonary embolism. Am J Cardiol (2002) 1.06
Clinical characteristics, aetiology and occurrence of type 2 acute myocardial infarction. Kardiol Pol (2013) 1.05
108th ENMC International Workshop, 3rd Workshop of the MYO-CLUSTER project: EUROMEN, 7th International Emery-Dreifuss Muscular Dystrophy (EDMD) Workshop, 13-15 September 2002, Naarden, The Netherlands. Neuromuscul Disord (2003) 1.04
Polish Registry of Acute Coronary Syndromes (PL-ACS). Characteristics, treatments and outcomes of patients with acute coronary syndromes in Poland. Kardiol Pol (2007) 1.03
Tryptase levels in patients after acute coronary syndromes: the potential new marker of an unstable plaque? Clin Cardiol (2003) 1.02
Pulmonary artery dilatation correlates with the risk of unexpected death in chronic arterial or thromboembolic pulmonary hypertension. Chest (2012) 0.98
Admission B-type natriuretic peptide assessment improves early risk stratification by Killip classes and TIMI risk score in patients with acute ST elevation myocardial infarction treated with primary angioplasty. Int J Cardiol (2006) 0.97
Altered gene expression pattern in peripheral blood mononuclear cells in patients with acute myocardial infarction. PLoS One (2012) 0.95
Baseline platelet size is increased in patients with acute coronary syndromes developing early stent thrombosis and predicts future residual platelet reactivity. A case-control study. Thromb Res (2009) 0.93